KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Divestments (2016 - 2026)

Gsk has reported Divestments over the past 18 years, most recently at $4.0 million for Q1 2026.

  • For Q1 2026, Divestments changed N/A year-over-year to $4.0 million; the TTM value through Mar 2026 reached -$1.9 billion, changed N/A, while the annual FY2025 figure was -$35.9 million, 55.45% down from the prior year.
  • Divestments for Q1 2026 was $4.0 million at Gsk, up from -$219.5 million in the prior quarter.
  • Over five years, Divestments peaked at $1.3 billion in Q1 2024 and troughed at -$3.0 billion in Q4 2024.
  • A 5-year average of -$155.8 million and a median of $4.0 million in 2026 define the central range for Divestments.
  • On a YoY basis, Divestments climbed as much as 10910.09% in 2024 and fell as far as 403.21% in 2024.
  • Year by year, Divestments stood at -$185.3 million in 2022, then soared by 641.81% to $1.0 billion in 2023, then crashed by 403.21% to -$3.0 billion in 2024, then soared by 92.79% to -$219.5 million in 2025, then surged by 101.84% to $4.0 million in 2026.
  • Business Quant data shows Divestments for GSK at $4.0 million in Q1 2026, -$219.5 million in Q4 2025, and -$3.0 billion in Q4 2024.